Physician profile
Daniel Dino
NPI 1326248105
$13,375.51
in general payments reported to CMS, 2019-2025
50 companies · $1,957 in 2025
The $1,957 reported for 2025 was more than what 94% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,580 · 2020: $1,169 · 2021: $1,971 · 2022: $2,137 · 2023: $2,323 · 2024: $2,238 · 2025: $1,957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,451 · Education: $66.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,451.11 |
| Education | $66.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,375.87 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Novo Nordisk INC | $1,325.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,104.81 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,038.47 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $952.37 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $842.74 | 2019-2025 | Evenity, Prolia, Repatha |
| Astellas Pharma US INC | $564.61 | 2019-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $530.30 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $490.83 | 2019-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $479.20 | 2021-2025 | Rexulti |
| Pfizer INC. | $405.95 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $402.98 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $295.03 | 2019-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Insulet Corporation | $270.63 | 2022-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $240.76 | 2024-2025 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Dino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.